Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
February 2008
Revised Date: 
September 2011
  • Treatment of vancomycin-resistant Enterococcus faecium (VREF) infections
  • Nosocomial & community acquired pneumonia,skin &  skin structure infections due to S.pneumonia, S.aureus (Methicillin susceptible & resistant strains), S.pyogenes, or S.agalactiae
  • Methicillin-resistant staphylococcal (MRSA) infections if failure or intolerance to vancomycin
Reconstitution and Stability: 
  • Available in 2 mg/mL single-dose premixed 300 mL bags
  • DO NOT further dilute
  • Store at room temperature
  • Keep infusion bags in overwrap until ready to use -protect from light
  • Solutions may exhibit a yellow colour than may intensify without adversely affecting potency

     - Solutions Compatible:  D5W, NS, ringer's lactate

    - Additives/Above Cassette Compatible:  cefazolin, ceftazidime, ciprofloxacin, gentamicin, tobramycin

    - Y-site Compatible:  acyclovir, amikacin, ampicillin, cefazolin, ceftazidime, ceftriaxone, cefuroxime ciprofloxacin, clindamycin, dexamethasome, dexmedetomidine, diphenhydramine, dobutamine, dopamine, fentanyl, furosemide, gentamicin, granisetron, heparin, hydromorphone, meropenem methylprednisolone sodium succinate, metronidazole, midazolam, morphine, potassium chloride, ranitidine, sodium bicarbonate, tobramycin, vancomycin

     - Incompatible:  amphoterin B, chlorpromazine, erythromycin, sulfamethoxazole/trimethoprim,


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IV Direct          NO
IV Intermittent Infusion

Usual dilution:  2 mg/mL
Infusion time:  30 - 120 minutes                               

IV Continuous Infusion NO




(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • 30 mg/kg/day  IV divided Q8H
  • Maximum: 1200 mg /day

Adolescent / adult:

  • 600 mg  IV Q12H
  • Maximum:  1200 mg/day
Potential hazards of parenteral administration: 
  • Myelosuppression (especially thrombocytopenia)
  • Hypertension
  • Nausea, diarrhea
  • Headache
  • Monitor CBC weekly
  • Reversible non-selective inhibitor of monamine oxidase
  • Avoid consuming foods/beverages with high tyramine content
  • Recommend to reduce doses of sympathomimetics, vasopressors, & dopaminergic agents prior to initiating linezolid
  • Patients on hemodialysis should receive linezolid after dialysis

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.